Locations:
Search
End-of-treatment VALOR-HCM analyses reassure on use in women, suggest disease-modifying potential
Phase 3 ODYSSEY-HCM trial of mavacamten leaves lingering questions about potential broader use
Few patients report left ventricular dysfunction or heart failure after one year
Avoidance of septal reduction therapy continues while LVEF dysfunction remains infrequent
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Serial strain assessments show sustained favorable impacts on LV systolic function and LA function
Logistic feasibility supported for treating obstructive HCM under the REMS program
Additional analyses of the two trials presented at 2023 ESC Congress
An abundance of promising studies are on the horizon
Gains are associated with clinical and biomarker benefits in obstructive HCM
Latest results confirm and build on 16-week findings
Advertisement
Advertisement